- freely available
Immunotherapy and Immune Evasion in Prostate Cancer
AbstractMetastatic prostate cancer remains to this day a terminal disease. Prostatectomy and radiotherapy are effective for organ-confined diseases, but treatment for locally advanced and metastatic cancer remains challenging. Although advanced prostate cancers treated with androgen deprivation therapy achieves debulking of disease, responses are transient with subsequent development of castration-resistant and metastatic disease. Since prostate cancer is typically a slowly progressing disease, use of immune-based therapies offers an advantage to target advanced tumors and to induce antitumor immunity. This review will discuss the clinical merits of various vaccines and immunotherapies in castrate resistant prostate cancer and challenges to this evolving field of immune-based therapies.
Share & Cite This Article
Thakur, A.; Vaishampayan, U.; Lum, L.G. Immunotherapy and Immune Evasion in Prostate Cancer. Cancers 2013, 5, 569-590.View more citation formats
Thakur A, Vaishampayan U, Lum LG. Immunotherapy and Immune Evasion in Prostate Cancer. Cancers. 2013; 5(2):569-590.Chicago/Turabian Style
Thakur, Archana; Vaishampayan, Ulka; Lum, Lawrence G. 2013. "Immunotherapy and Immune Evasion in Prostate Cancer." Cancers 5, no. 2: 569-590.
Notes: Multiple requests from the same IP address are counted as one view.